Cite this article: Hristova M, Atanassova P (2016) Plasma Levels of Cortisol, Leptin and an Expression of the Leptin Receptors in the Visceral Adipose Tissue in Case of Metabolic Syndrome. J Endocrinol Diabetes Obes 4(2): 1086.
*Corresponding authorMariyana Georgieva Hristova, Department of Endocrinology, Medical Center of Varna, 17 Mur Str., entr. 2, Varna 9003, Bulgaria, Tel/Fax: 359-52-37-23-23; Email:
Plasma Levels of Cortisol, Leptin and an Expression of the Leptin Receptors in the Visceral Adipose Tissue in Case of Metabolic SyndromeMariyana Hristova1* and Pepa Atanassova2
1Department of Endocrinology, Medical Center of Varna, Bulgaria2Department of Anatomy, Histology and Embryology, Medical University, Bulgaria
Abstract
The systemic studies in the recent years have proved the understanding that neuroendocrine changes play a main role in the phatogenesis of central obesity, hypertension, insulin resistance, leptin resistance. These changes involve disorders of the hypothalamo-pituitary-adrenal axis activated after operiods of prolonged stress and enviroumental stress factors.
Aim ofr this study is to look for the connection between the high plasma levels of cortisol, leptin and the expression of leptin receptors in the visceral adipose tissue in patients with metabolic syndrome. We have found positive correlation between the body mass index, the area of the visceral adipose and the plasma levels of cortizol and leptin in cases of increased expression of the leptin receptors.
INTRODUCTIONThe adipose tissue is an endocrine organ with key regulatory
function, also commu nicating with the brain and the peripheral tissues [1–3].
The adipose organ consists of two types of tissue - white and brown (visceral) adipose tissue, each of which is characterised by specific vascularisation, innervation and cell structure. All subcutaneous and visceral depots contain both white and brown tissue, whose relative quantity depends on the age, environmental temperature and the hormonal levels in the organism. The mature brown adipocytes show charac teristic polyfacet lipid drops and typical mitochondria, however this happens only when they receive adequate beta-adrenergic stimuli. In case of lack of such stimuli, the brown adipocytes turn into cells, which are morphologically similar to the white adipocytes producing leptin. The stimulation of ventromedial hypothalamus leads to over-activation of the sympathetic nerves and the β3-adrenergic receptors, which leads to increased thermogenesis [4].
The abdominal (visceral, android, central) obesity is a characteristic feature of met abolic syndrome (MS). It is combined with increased activation of the hypothalam ic-pituitary-adrenal axis with subsequent sympathicotony and increased secretion of cortisol from the adrenal [5,6]. Sympathicotony and hormonal
imbalance are char acteristic for chronic stress (emotional and/or chronic inflammatory), which are eti ological factors for MS [7].
The increased plasma cortisol in the presence of hyperinsulinemia in MS leads to accumulation of masts in the visceral depot of the organism.
Visfatin could play an important role in the fast accumulation of visceral adipose tissue through autocrine and paracrine route [8].
With reduction of the visceral adipose tissue, the signal for fullness to the hypothala mus is reduced and this leads to hyperphagia. The intact thermogenesis in the viscer al adipose tissue is important for the occurrence of the leptin anorexigenic effect on neuropeptide-tyrosine (NPY). Hypercortisolemia is found in patients with MS. It is found that glucocorticoids have stimulating effect on the expression of the ob-gene and increase the expression of leptin receptors [9,10].
Therefore we set the objective to search for a link between the high plasma levels of cortisol and the expression of leptin receptors in the visceral adipose tissue in patients with MS.
MATERIALS AND METHODS23 patients with MS (20 women and 3 men) have been studied,
who were diagnosed based on the criteria of the Adult Treatment
CentralBringing Excellence in Open Access
Hristova et al. (2016)Email:
J Endocrinol Diabetes Obes 4(2): 1086 (2016) 2/4
Panel III of the American National Cho lesterol Program and 10 controls (7 women and 3 men), respectively by gender and age, with no family history of diabetes mellitus or premature coronary atheroscle rosis disease (documented cardiovascular disease in at least one immediate family member under 55 years of age for men and under 60 for women). The studies have been carried out based on the Helsinki Convention.
METHODS Leptin and cortisol have been studied - radio-immunoassay):
Ten days before the blood and adipose tissue sampling, the medication treatment has been ceased. The blood samples have been taken between 8.00 and 9.00 in the morning from the antecubital vein and have been centrifuged immediately - 8500g for 20 minutes at 4°С in order to remove the cells.
Plasma cortisol has been tested based on the radio-immunoassay method.
Plasma leptin was studied through radio-immunoassay. It has been studied with a kit for Alpha Diagnostics, San Antonio, TX, USA.
Histological study: Biopsy of abdominal, mesenteric adipose tissue, fixation in 4% paraformaldehyde, in 0.1 phosphate solution, pH 7.4 for 4 days at temperature of 4°C. Sections with thickness of 15 μm have been prepared by using cryomicrotome for histological evaluation.
Measurement of the visceral adipose tissue area in cm2 and density in Hunsfield units through computer axial tomography (CAT) at the level of the third lumbar vertebra (L3).
Biopsy from the visceral adipose tissue (mesenteric) and immuno-histochemical definition of the expression of leptin receptors in this adipose tissue.
Statistical method - analysis of variance (ANOVA).
The data from the CAT of adipose tissue have been processed with software pack IAS 2000.47.
RESULTSThe body mass index in MS has an average value of 39.56±1.00
and 22±57 in the controls.
The plasma levels of cortisol in MS are 525.08±33.83 nmol/l and 368.00±14.89 nmol/l in the controls.
A suppressant test with 2 mg dexamethasone was performed - a suppression was achieved, which excluded Cushing’s syndrome.
Besides the high plasma levels of cortisol, the study of the 24-hour rhythm of corti sol in MS showed disturbed rhythm.
The plasma levels of leptin are significantly higher in MS - 6.76±2.95 ng/ml and 1.13±0.15 ng/ml in the controls.
In patients with MS the area is 157.24±30.14 and it is 100.65±34.29 in the controls. The visceral adipose tissue with MS has density of 19109.68±3066.5 pixels and 13649.18±4099.6 pixels in the controls.
Summary: The visceral adipose tissue in MS is with
statistically significantly higher area and density as compared to the controls (р<0.05).
DISCUSSIONThe high levels of cortisol in case of MS, as well as the
disturbed 24-hour rhythm of cortisol give the ground to assume hyperactivation of the hypothalamus-pituitary-ad renal axis in case of MS and disturbed hypothalamic feedback control mechanism. The high plasma levels of cortisol are an important factor for the increased lipogen esis in МС.
The increased plasma levels of leptin in MS (Figure 1) (Table 1), in combination with increased appetite of these patients also support the presence of disorder in the hypothalamic feedback control mechanism on appetite.
We have found positive correlation between the body mass index (BMI), the area of the visceral adipose tissue and the plasma levels of cortisol and leptin in cases of increased expression of the leptin receptors. This high expressions of the leptin re ceptors shows that the visceral adipose tissue is an important target for the action of leptin. The results confirm the important regulatory and metabolic role of leptin for increasing the thermogenesis in the visceral adipose tissue.
It is proven that leptin inhibits the preadipocyte differentiation and the lipogenesis in cell cultures through paracrine and autocrine mechanism of action. Leptin stimulates the lipolysis in adipocytes. On the other hand, the high cortisol levels in plasma have stimulating effect on the expression of leptin receptors [9]. This was confirmed by our results.
Figure 1 Results from defining the expression of leptin receptors in the visceral adipose tissue – MS_Ob-R.
Table 1: Clinical and laboratory characteristics of patients with MS – generalised stage (N=23) and healthy controls (n=10).
Controls MS generalised stage
Age 42.50 ±2.75 45.69 ±2.18 NS
Body mass (kg) 64.80 ±1.98 100.47 ±3.43 p<0.01Body mass index
The high levels of plasma cortisol explain why the expression of leptin receptors in the visceral adipose tissue is significantly high in case of high plasma levels of leptin.
In summary – the visceral adipose tissue is characterised by high metabolic and lipolytic activity [11].
The high plasma levels of cortisol, in the presence of hyperinsulinemia, lead to in creased lipogenesis in the visceral depot of the adipose tissue. Visfatin, which is a product of the visceral adipose tissue, also participates in the increased lipogenesis.
At the same time, hypercortisolemia in MS enhances the expression of the leptin receptors in the visceral adipose tissue and this leads to increased lipolysis and in creased release of fatty acids in the portal vein. This is followed by increased synthe-sis of triglycerides and cholesterol from the liver, increased gluconeogenesis and the atherogenic lipid profile, which is characteristic for MS. It is controversial whether lipolysis is balanced by the respective storage of a large quantity of fat [12].
It is proven that for the presence of the regulatory effect of the white adipose tissue on appetite through the anorexigenic effect of leptin, presence of sufficiently large depot for visceral adipose tissue and preserved thermogenesis is necessary. This is probably cross-talk between adrenal glands, the white and visceral adipose tissue through the adipokines and under the control of the brain (hypothalamus).
The over-accumulation of visceral adipose tissue causes dysfunction of the adipo cytes and imbalance of adipokines, which leads to metabolic and circulation dis eases and atherosclerosis [13]. The participation of mastocytes in MS and the new adipose-immune link leptin-mastocytes was established [14].
The secretion of the adipose tissue constitutes a new target for pharmacology [15,16]. Recently, the metabotrophic effect of neurotrophins and the participation of NGF and BDNF in the pathogenesis of obesity, type 2 diabetes mellitus and metabolic syndrome was proven [7,17-25]. Hyperneurotrophinemia in the early stages of MS and the subsequent hyperacti vation of the hypothalamo—pituitary—adrenal axis leads to changes in the rhythm of cortisol secretion and changes in the frequency and amplitude of the pulsations in cortisol and adrenalin secretion. This is likely to account for the reduced sensitivity of the leptin receptors in the hypothalamus. Glyco- corticoids are counterregulatory hormones for leptin. Probably all the above results in leptin resistance [27]. Corti sol has an permissive effect on NPY secretion by the paraventricular nuclei in the 35
hypothalamus. In hypercortisolemia the NPY secretion is increased irrespective of the high plasma levels of leptin. The feedback mechanism is also disturbed for hy pothalamic control of the food intake and energy spending with subsequent central obesity. We can summarize that the appropriate therapeutical approach requires the recov ery of the balance between the nervous, endocrine and immune systems. This can be achieved through the elimination of the chronic inflammatory and the chronic psychosocial stress (distress) and adequate control over hyponeurotrophinemia [28].
REFERENCES1. Trayhurn P. Endocrine and signalling role of adipose tissue: new
perspectives on fat. Acta Physiol Scand. 2005; 184: 285-293.
2. Trayhurn P. The biology of obesity. Proc Nutr Soc. 2005; 64: 31-38.
3. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006; 74: 443-477.
4. Barbatelli G, Murano I, Cinti S. The emergence of cold-induced brown adipocytes in mouse white fat depost is determind predominantly by white to brown adipocyte transdifferentiation. Am J Physiol Endocrinol Metab. 2010; 298: 1244–1253.
5. Rosmond R, Björntorp P. Blood pressure in relation to obesity, insulin and the hypothalamic-pituitary-adrenal axis in Swedish men. J Hypertens. 1998; 16: 1721-1726.
6. Björntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med. 1999; 16: 373-383.
7. Hristova M, Aloe L. Metabolic syndrome--neurotrophic hypothesis. Med Hypotheses. 2006; 66: 545-549.
8. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307: 426-430.
9. Halleux CM, Servais I, Reul B A, Detry R, Brichard SM. Multihormonal control of ob-gene expression and leptin secretion from cultured human visceral adipose tissue: increased responsiveness to glucocorticoids in obesity. J Clin Endocrinal Metab. 1998; 83: 902–910.
10. Bullo M, Garcia-Lorda P, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor and leptin expression. Obesity Research 2003; 11: 525–531.
11. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000; 21: 697-738.
12. Frayn KN. Visceral fat and insulin resistance--causative or correlative? Br J Nutr. 2000; 83: 71-77.
13. Matsuzawa Y. Adipocytokines and metabolic syndrome. Semin Vasc Med. 2005; 5: 34-39.
14. Hristova M, Aloe L, Ghenev P, Fiore M, Chaldakov G. Leptin and Mast cells: A novee adipoimmune Link. Turk J Med Sci. 2001; 581–583.
15. Chaldakov G, Fiore M, Hristova M, Aloe L. Cell Biology and pharmacology of adipose tissue sectretion. Fabad J Pharm Sci. 2000; 25, 181-191.
16. Chaldakov GN, Stankulov IS, Hristova M, Ghenev PI. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des. 2003; 9: 1023-1031.
17. Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res. 2004; 146: 279-289.
18. Chaldakov GN, Fiore M, Hristova MG, Aloe L. Metabotrophic potential of neurotrophins:implication in obesity and related diseases? Med Sci Monit. 2003; 9: HY19-21.
19. Chaldakov GN, Fiore M, Stankulov IS, Hristova M, Antonelli A, Manni L, et al. NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. Arch Physiol Biochem. 2001; 109: 357-360.
Hristova M, Atanassova P (2016) Plasma Levels of Cortisol, Leptin and an Expression of the Leptin Receptors in the Visceral Adipose Tissue in Case of Metabolic Syndrome. J Endocrinol Diabetes Obes 4(2): 1086.
Cite this article
Erikstrup C, et al. Brain-derived neurotrophic factor /BDNF and type 2 diabetes. Diabetologia. 2007; 50: 431–438.
21. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med. 1999; 38: 202-206.
22. Julius S. Sympathetic overactivity and insulin resistance in hypertension. SNS Report. 2000; 1: 2–3.
26. Chaldakov G, Fiore M, Tonchev A, Hristova M. The adipose tissue: a new member of the difluse neuroendocrine system? Adipobiology. 2009; 1: 87-93.
27. Zakrzewska K, Cusin, Sairsbury A, Jeanrenaud R, Jeanre- naud B. Glucocorticoids as counterregulatory hormones of leptin. Toward an understanding of leptin resistance. Diabetes 1997; 46: 717-719.
28. Alloe L, Tirassa P, Bracci-Laudiero L. NGF in neurological and non-neurological diseases: basic findings and emerging pharmaceutical perspectives. Curr Pharm Des 2001; 7: 113-123.
